Advertisement

Recurrence of ROP After Anti-VEGF Treatment

  • Ulrich Spandau
  • Sang Jin Kim
Chapter

Abstract

This chapter is about recurrence of ROP after anti-VEGF treatment. The clinical course and timing of recurrence after anti-VEGF treatment is clarified. Furthermore, major clinical studies about the incidence of recurrence after anti-VEGF treatment for ROP are summarized.

Keywords

Recurrence of ROP Anti-VEGF Recurrence ROP 

References

  1. 1.
    Darwish D, Chee RI, Patel SN, Jonas K, Ostmo S, Campbell JP, Chiang MF, Chan RVP. Anti-Vascular endothelial growth factor and the evolving management paradigm for retinopathy of prematurity. Asia Pac J Ophthalmol (Phila). 2018;7:136–44.Google Scholar
  2. 2.
    Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after Intravitreal Bevacizumab monotherapy. Ophthalmology. 2016;123:1845–55.CrossRefGoogle Scholar
  3. 3.
    Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP. Very late reactivation of retinopathy of prematurity after monotherapy with Intravitreal Bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2016;47:280–3.CrossRefGoogle Scholar
  4. 4.
    Hajrasouliha AR, Garcia-Gonzales JM, Shapiro MJ, Yoon H, Blair MP. Reactivation of retinopathy of prematurity three years after treatment with Bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2017;48:255–9.CrossRefGoogle Scholar
  5. 5.
    Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.CrossRefGoogle Scholar
  6. 6.
    Wallace DK, Dean TW, Hartnett ME, Kong L, Smith LE, Hubbard GB, McGregor ML, Jordan CO, Mantagos IS, Bell EF, Kraker RT, Pediatric Eye Disease Investigator Group. A dosing study of Bevacizumab for retinopathy of prematurity: late recurrences and additional treatments. Ophthalmology. 2018;7  https://doi.org/10.1016/j.ophtha.2018.05.001.CrossRefGoogle Scholar
  7. 7.
    Chen SN, Lian I, Hwang YC, Chen YH, Chang YC, Lee KH, Chuang CC, Wu WC. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina. 2015;35:667–74.CrossRefGoogle Scholar
  8. 8.
    Gunay M, Sukgen EA, Celik G, Kocluk Y. Comparison of Bevacizumab, Ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2017;42:462–9.CrossRefGoogle Scholar
  9. 9.
    Stahl A, Krohne TU, Eter N, Oberacher-Velten I, Guthoff R, Meltendorf S, Ehrt O, Aisenbrey S, Roider J, Gerding H, Jandeck C, Smith LEH, Walz JM, Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity (CARE-ROP) Study Group. Comparing alternative Ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. 2018;172:278–86.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Ulrich Spandau
    • 1
  • Sang Jin Kim
    • 2
  1. 1.OphthalmologyUniversity of Uppsala OphthalmologyUppsalaSweden
  2. 2.Department of OphthalmologySamsung Medical Center, Sungkyunkwan UniversitySeoulSouth Korea

Personalised recommendations